Brokers Issue Forecasts for CASI Q1 Earnings

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for CASI Pharmaceuticals in a research report issued on Wednesday, April 9th. HC Wainwright analyst S. Lee forecasts that the biotechnology company will post earnings per share of ($0.61) for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.08) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($1.03) EPS.

Separately, StockNews.com began coverage on shares of CASI Pharmaceuticals in a report on Saturday. They issued a “hold” rating for the company.

CASI Pharmaceuticals Trading Up 4.7 %

Shares of CASI Pharmaceuticals stock opened at $2.00 on Friday. The business has a fifty day simple moving average of $2.27 and a 200-day simple moving average of $3.52. The firm has a market cap of $24.60 million, a price-to-earnings ratio of -0.90 and a beta of 0.66. CASI Pharmaceuticals has a fifty-two week low of $1.88 and a fifty-two week high of $7.67. The company has a quick ratio of 2.32, a current ratio of 3.20 and a debt-to-equity ratio of 1.38.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.19). CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%. The firm had revenue of $13.36 million for the quarter, compared to the consensus estimate of $7.39 million.

Institutional Trading of CASI Pharmaceuticals

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Foresite Capital Management VI LLC bought a new position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,329,383 shares of the biotechnology company’s stock, valued at approximately $3,762,000. CASI Pharmaceuticals makes up about 1.7% of Foresite Capital Management VI LLC’s portfolio, making the stock its 13th largest holding. Foresite Capital Management VI LLC owned about 8.58% of CASI Pharmaceuticals as of its most recent SEC filing. 22.23% of the stock is owned by institutional investors and hedge funds.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.